A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A. Bhat, Myron S. Czuczman, Kelvin P. Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J. Hernandez-Ilizaliturri Clinical Lymphoma, Myeloma and Leukemia Volume 18, Issue 1, Pages e51-e60 (January 2018) DOI: 10.1016/j.clml.2017.09.003 Copyright © 2017 Elsevier Inc. Terms and Conditions
Figure 1 Dose Schedule Administration of Pegfilgrastim Combined With Rituximab. Pegfilgrastim 6 mg Subcutaneously Was Administered 3 Days (Day 1 of Each Treatment Week) Before Each Dose of Rituximab 375 mg/m2 Intravenously (Day 4 of Each Treatment Week) Clinical Lymphoma, Myeloma and Leukemia 2018 18, e51-e60DOI: (10.1016/j.clml.2017.09.003) Copyright © 2017 Elsevier Inc. Terms and Conditions
Figure 2 Kaplan-Meier Survival Curves. (A) Progression-free Survival in Whole Cohort (n = 20). (B) Overall Survival in Whole Cohort (n = 20). (C) Overall Survival Stratified by Disease Type (Follicular Lymphoma vs. Other Histologic Types) Abbreviation: CI, confidence interval. Clinical Lymphoma, Myeloma and Leukemia 2018 18, e51-e60DOI: (10.1016/j.clml.2017.09.003) Copyright © 2017 Elsevier Inc. Terms and Conditions
Figure 3 Progression-free Survival Was Longer in Patients With a Shorter Time to Reach Peak Oxidative Burst Abbreviation: MFI, mean fluorescence intensity. Clinical Lymphoma, Myeloma and Leukemia 2018 18, e51-e60DOI: (10.1016/j.clml.2017.09.003) Copyright © 2017 Elsevier Inc. Terms and Conditions